STOCK MARKET BSE NSE

In a fresh report, national AEFI panel confirms 55 severe adverse events after COVID-19 shots

A total of five cases, that included a death after administration of Covishield in a 57-year-old male in February, however, were found to be “coincidental”, not directly linked with vaccination.

Published: 18th July 2021 06:49 PM  |   Last Updated: 18th July 2021 06:49 PM   |  A+A-

A health worker prepares to administer the Covishield vaccine to a woman at a government hospital in Noida. (Photo | AP)

A health worker prepares to administer the Covishield vaccine to a woman at a government hospital in Noida. (Photo | AP)

Express News Service

NEW DELHI: The national Adverse Effects Following Covid-19 Immunization (AEFI) committee has approved reports for 60 more serious adverse events, ruling that 55 cases, the majority of which needed hospitalization, were associated with vaccination as per the causality assessment. 

A total of five cases, that included a death after administration of Covishield in a 57-year-old male in February, however, were found to be “coincidental”, not directly linked with vaccination.

The report is based on an assessment of 60 serious adverse events—three of which were recorded following Covaxin jabs while the rest were registered after administration of Covishield- by the national panel on May 27 and was submitted to the Union ministry of health and family welfare on July 8.

Before this, in June, releasing the first national report on causality assessment of 31 serious AEFI cases, the Centre had recorded India’s first Covid19 vaccine-related death since the start of the coronavirus vaccination campaign while seven other post-vaccination deaths were declared as “indeterminate" indicating there is no evidence to connect them to the vaccines.

The confirmed death due to the Covid-19 vaccine was reported in a 68-year-old male on March 21 and the reason was anaphylaxis or severe allergic reaction to the jab but it's not clear whether the person had received Covishield or Covaxin.

The latest report says that 36—out of 60- were anxiety-related reactions, and 18 were vaccine product-related reactions, and one was classified as both vaccine product-related and anxiety-related reaction.

However, five cases were found to have inconsistent causal association to vaccination, (coincidental - not linked to vaccination) of which one was a death case.

“Overall, the benefits of vaccination are overwhelmingly greater than the small risk of harm. However, as a measure of utmost precaution, all emerging signals of harm are being constantly tracked and reviewed periodically,” the report by the committee, headed by N K Arora said.

The report further explained that vaccine product-related reactions are expected reactions that can be attributed to vaccination based on current scientific evidence, examples of such reactions are allergic reactions and anaphylaxis.

Those watching the follow up of adverse events following Covid19 shots meanwhile said that while release of this bulletin is a positive step, the committee seems to be sitting on “difficult AEFI cases”.

“Majority of the cases assessed include anxiety reactions while the committee is not releasing its report on a huge pile of cases of deaths and hospitalisations,” said Malini Aisola of the All-India Drug Action Network. 

“I just wish that the AEFI assessment process is faster and more transparent.”

ALSO WATCH:



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp